Search This Blog

Friday, December 6, 2019

Bristol-Myers and bluebird bio’s CAR T successful in mid-stage myeloma study

Bluebird bio (NASDAQ:BLUE) and licensee Bristol-Myers Squibb (NYSE:BMYannounce positive topline results from a Phase 2 clinical trial, KarMMa, evaluating CAR T therapy idecabtagene vicleucel (ide-cel) (bb2121) in treatment-resistant multiple myeloma (MM) patients.
The study met the primary and key secondary endpoints. Specifically, the overall response rate (ORR) was 73.4% (n=94/128) across three doses (primary endpoint). The response rate was dose-dependent, 50.0% (n=2/4) in the lowest, 68.6% (n=48/70) in the middle and 81.5% (n=44/54) in the highest. The complete response rates were 25%, 28.6% and 35.2%, respectively.
Median duration of response was 10.6 months and median progression-free survival was 8.6 months.
The safety profile was consistent with the Phase 1 CRB-401 trial. The rate of serious/life-threatening/fatal cytokine release syndrome (CRS) was 5.5% (n=7/128) including one death. CRS of any grade occurred in 83.6% of subjects (n=107/128). The rate of serious neurotoxicity events was 3.1% (n=4/128).
More detailed data will be submitted for presentation at a future medical conference.
BMY and BLUE are both up 1% after hours.

Why people buy, trade, donate medications on the black market

Altruism and a lack of access and affordability are three reasons why people with chronic illnesses are turning to the “black market” for medicines and supplies, new research shows. Scientists at University of Utah Health and University of Colorado ran surveys to understand why individuals are looking beyond pharmacies and medical equipment companies to meet essential needs. The reasons listed were many but centered on a single theme: traditional healthcare is failing them.
Instead, people with chronic conditions, like diabetes, are turning to online resources that are more typically associated with gift shopping. They are scrolling through craigslist, browsing for second-hand goods on eBay and searching social media message boards. Rather than toys and sweaters, they are looking for leads to medications and supplies like glucose strips for measuring blood sugar, and insulin, a drug they must take regularly to keep their blood sugar in control.
“People have to make a decision. Do they want to maintain their health? And if so, what are the medications and tools that they need in order to stay healthy?” explains Michelle Litchman, Ph.D., FNP-BC, lead author of the study and a nurse practitioner and researcher at the College of Nursing at U of U Health. “In some cases, people have had to go to extreme measures and find a network that can supply their healthcare needs.”
Results from the study were published online in the Journal of Diabetes Science and Technology.
An online survey of 159 people with diabetes and their caregivers showed the group had participated in different types of underground exchange activities, from donating (56%) to receiving donated goods (34%) to trading (24%), borrowing (22%) and purchasing (15%). Many had taken part in more than one kind of transaction.
When asked why they turned to underground exchange, lack of affordability and accessibility were frequently mentioned. These comments supported statistics showing that over half of participants in the study engaged in underground exchange activities out of financial necessity. People donated and traded with family, friends and strangers who could not get supplies themselves, despite most having health insurance.
In other instances, it was bureaucracy that got in the way. Delays in approval, filling a prescription or shipping prevented some individuals from getting supplies by the time they were medically needed. As a result, some resorted to making trades or accepting donations in order to meet their needs quickly and avoid hospitalization.
“I most likely would have ended up with ketoacidosis but I was lucky enough to get insulin from another person,” wrote one survey participant.
Listen to an interview with Litchman about how people with diabetes are foregoing basic needs and taking part in underground trading just to stay healthy.
“People with diabetes resort to underground exchange of diabetes supplies and medications not because they want to, not to turn a quick profit, but because their needs aren’t being met,” says the study’s senior author Sean Oser, M.D., University of Colorado, Denver. “Some turn to others to get what they need to feel safe.”
Many weren’t engaging in underground trading for themselves, but rather had excess items they knew others could use. “I… donate supplies to people who need them because it’s not fair for me to have excess while they struggle to survive, or even die, because our healthcare system is broken,” wrote another participant. In fact, altruism was a prevailing motivation behind underground exchange. Some reported feeling a strong desire to help others within the diabetes community but at the same time were aware that circumstances are volatile. Someone who is in a position to donate supplies on one day could become a person in need on the next.
A downside to acquiring medications and supplies outside the traditional health care system is lack of safety oversight, the study’s authors say. However, fewer than 1% of study participants who made transactions through underground markets reported safety concerns. Those that occurred included receiving faulty equipment and unrefrigerated insulin, although recipients did not experience ill effects. Still, the authors indicate there is plenty of room for additional error. Poor shipping conditions could spoil medications without the recipient knowing. Another risk could be someone taking the wrong medication if it were inadvertently provided to them. Despite these risks, people continue to use underground exchanges because at this stage there are few alternatives, says Litchman.
Participants of the survey were mostly Caucasian women with a college education. Next steps will be to carry out larger studies that sample individuals across the country, including participants with varied income levels and of different ethnicities to provide a more comprehensive picture of underground exchange and its impacts on the public. In any case, Litchman says that the black market for medications doesn’t appear to be going away soon.
“Underground trading of medications and supplies isn’t ideal. But what other real solutions exist so that people can actually get what they need without increasing bureaucratic delays and burden?” Litchman says. “Our study points to an urgent need to improve access to medications that are essential for life.”
###
In addition to Litchman, co-authors are Sarah E. Wawrzynski, and Heather R. Walker from U of U Health and Tamara K. Oser and Sean Oser from University of Colorado, Denver.
The research published as “The Underground Exchange of Diabetes Medications and Supplies: Donating, Trading, and Borrowing, Oh My!” and was funded by the U of U Health College of Nursing and the Health Equity Resilience and Education Research Equity Team.

Leukemia, lymphoma squarely in sights of new class of drugs

UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2.
“This is a new class of drugs called PROTACs that target an essential survival protein in cancer cells called BCL-XL,” said research co-author Robert Hromas, M.D., FACP, professor of medicine and dean of the university’s Joe R. and Teresa Lozano Long School of Medicine. “The previous drugs that have targeted BCL-XL decrease platelets dangerously, with a high risk of bleeding. Our drug markedly reduces that risk, and thus would be potentially far more useful in cancer patients.”
The PROTAC reported here would treat T-cell malignancies such as T-cell acute leukemia and T-cell lymphoma, Dr. Hromas, a noted hematologist and oncologist, said.
T cells are produced by a gland in the upper chest called the thymus. These cells are very important participants in the body’s immune response. When they turn cancerous, they rely on BCL-XL for survival.
Dr. Hromas is joined on the paper by several co-authors from the Greehey Children’s Cancer Research Institute at UT Health San Antonio.
“PROTAC drugs degrade the BCL-XL protein rather than merely inhibiting it,” said Peter Houghton, Ph.D., professor of molecular medicine and director of the Greehey Institute. “Potentially this class of drug can be developed against certain childhood cancers that have been untreatable.”
###
Reference: “A selective BCL-XL degrader achieves safe and potent antitumor activity,” Nature Medicine, Sajid Khan, et al.
Funding: National Institutes of Health and the Cancer Prevention and Research Institute of Texas.

Despite Obesity Epidemic, Doctors Don’t Prescribe Obesity Drugs

“Weight-loss medications are rarely prescribed to eligible patients,” say the authors of a newly published study of prescribing patterns in more than 2 million Americans from 2009 to 2015.
The study by David R. Saxon, MD, an endocrinologist at the University of Colorado, in Aurora, found that overall, only 1.3% of eligible patients filled a prescription for an antiobesity medication, and prescribing rates ranged from 0.6% to 2.9%. It was first reported by Medscape Medical News at Obesity Week 2017.
A key finding was that more than 75% of prescriptions for obesity drugs were for phentermine, and just a quarter of physicians surveyed prescribed 90% of all the obesity drugs.
These results “illustrate the obesity treatment conundrum: why, despite five effective FDA-approved drugs for weight loss, is the highly prevalent problem of obesity undertreated?” says Willian H. Dietz, MD, PhD, a public health expert at the George Washington University, Washington, DC, in an editorial that accompanies the published study.
Both appear in the December issue of Obesity.
Dietz goes on to suggest several reasons for the low uptake of these drugs, but he puts the onus on healthcare providers to improve this number.
“The most effective strategy may be to recognize that obesity is a disease and needs to be treated as such and to hold providers accountable for the care that they provide or don’t,” he concludes.

Main Findings From Data From PORTAL Network

Saxon and colleagues analyzed electronic health records from 2009 to 2015 from participants in the Patient Outcomes Research To Advance Learning (PORTAL) network, which is funded by the US Patient-Centered Outcomes Research Institute.
They identified 2,248,407 patients who were eligible for weight-loss medications — ie, they had a body mass index ( BMI) > 30 kg/m2 or a BMI between 27 and 29.9 kg/m2 with at least one weight-weight-related comorbidity — from eight healthcare organizations: HealthPartners, Denver Health, and Kaiser Permanente Northwest, Southern California, Mid-Atlantic, Hawaii, Colorado, and Washington state.
They also identified primary care and other providers who had written prescriptions for these drugs
The 6-year study period covered the time before, and after, the US Food and Drug Administration (FDA) announced the removal of sibutramine for the treatment of obesity from the market (October 2010) .
It also covered the time before and after the agency approved new weight-loss medications: lorcaserin (Belviq, Eisai) in May 2012, phentermine/topiramate extended release (Qsymia, Vivus) in July 2012, naltrexone/bupropion sustained release (Contrave, Currax) in September 2014, and liraglutide 3.0 mg (Saxenda, Novo Nordisk) in December 2014.
In addition to the low uptake, the main findings were as follows:
  • 77% of the scripts were for phentermine, which, more than half of the time, was prescribed for longer than the 3 months it was approved for in 1959.
  • Diethylpropionorlistat, sibutramine, and locaserin accounted for 12.2%, 4.3%, 2.8%, and 2% of scripts, respectively.
  • Women, blacks, and patients with higher BMIs were more likely to receive a prescription.
  • 24% of the prescribers accounted for 90% of all filled prescriptions.
  • In 2015, just 2.7% of the prescribed drugs were for one of the newer agents.

Possible Reasons for Undertreatment

Dietz suggests that the following factors may contribute to the very low rates of prescribing of antiobesity drugs that Saxon and colleagues found:
  • Lack of recognition in the patient’s chart that the patient has obesity: “If obesity is not recognized, it should be no surprise that it is not treated,” Dietz writes.
  • Lack of patient demand: patients may not expect or ask their provider for advice regarding weight loss.
  • Provider knowledge: in a 2016 survey, “only 8% of providers correctly identified the recommended threshold for the initiation and continuation of pharmacotherapy for obesity.”
  • Provider bias: “69% of people with obesity reported experiencing weight-loss bias from physicians.”
  • Time and cost: “Few providers and patients may be able to meet the recommendation of the US Preventive Services Task Force (USPSTF) that patients with obesity receive intensive behavioral therapy delivered in 12 to 26 visits over the course of a year” and insurance plans may limit counseling and may not cover pharmacotherapy.
  • Provider and patient knowledge: Even if antiobesity pharmacotherapy is covered, “providers and patients may not be aware of the benefit.”

How to Remedy This?

The main strategy to stop the obesity pandemic is for providers to treat obesity as a disease, stresses Dietz.
In addition, patients need to ask for appropriate care, in shared decision making with providers.
And federal and state policy makers need to ensure that public health insurance programs cover FDA-approved drugs for obesity.
The study was funded by Kaiser Permanente, HealthPartners, and Denver Health through a Patient-Centered Outcomes Research Institute (PCORI) award. Saxon and other coauthors were also supported by grants from the NIH and the Veterans Affairs (VA). The authors have disclosed no relevant financial relationships. Dietz reports receiving research grants from Novo Nordisk and the Kresge Foundation, holding consulting positions with the National Academy of Medicine Roundtable on Obesity Solutions and WW (formerly Weight Watchers), and serving on boards for Partnership for a Healthier America and the JPB Foundation.
Obesity. December 2019. Full textEditorial

Correvio slumps as FDA staffers say heart med benefits do not outweigh risk

U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp’s heart drug said on Friday they did not believe the benefits of the therapy outweighed its risks, sending the company’s shares down nearly 38%.
The drug, Brinavess, approved in Europe and other countries including Canada, aims to correct erratic heart rhythm in the upper heart chambers due to a condition known as atrial fibrillation or AFib.
Although Correvio has provided evidence of benefits, Brinavess comes with “serious liabilities” including low blood pressure, irregular heartbeats in the lower heart chambers, and death, the FDA staffers said in documents released on Friday.
They also said the risk and management data provided by Correvio did not provide reassurance about the safe use of Brinavess.
A panel of independent experts to the FDA is set to convene on Tuesday to vote on the drug’s approval – an influential factor in the agency’s final decision that is expected by Dec. 24.

“While the company and its advisors will present its side… and bring experts to the (meeting) who will say that Brinavess is needed and can be used safely, we believe based on the FDA review to date, the odds are stacked against Brinavess,” Bloom Burton Securities analyst David Martin said.
Safety concerns led the FDA to decline approval to Brinavess in 2006 and later put trials on clinical hold as a patient with no apparent heart issues died after being administered Correvio’s drug. The hold still remains in place.
AFib, a common cardiac rhythm disturbance, is a leading cause of stroke. The condition affects about 2.7 million to 6.1 million Americans every year, according to the American Heart Association.
“Despite the cautious tone of the materials, we still believe there is a large unmet need for a drug like Brinavess and we are hopeful the Agency can find a path to approval,” Cantor Fitzgerald analyst Louise Chen said in a client note.

Current treatments for AFib include medication to regulate heart rhythm, blood thinners to prevent clot formation, and even, electric shocks to reset the heartbeat.
U.S.-listed shares of the Canadian drugmaker were trading lower at $1.32 in early morning trading.

Swiss approve insurance cover for Novartis, Gilead cell therapies

The Swiss government approved on Friday health insurance coverage for CAR-T cell therapies from Novartis and Gilead Sciences, which can cost hundreds of thousands of dollars per patient.
In this form of therapy, patients’ white blood cells are genetically modified to attack cancer cells.
The health department said the decision covered Novartis’s Kymriah and Gilead’s Yescarta.
“The contract between hospitals and the health insurers will be approved until the end of 2020, granting the affected patients immediate access to these therapies,” the government said after a cabinet meeting.

Grifols says trial shows positive effects in slowing Alzheimer’s

Spain’s Grifols said on Friday the latest results from a clinical trial of its Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
The results of its AMBAR trial were unveiled at a conference in San Diego, the Barcelona-based company said in a statement to the Spanish stock regulator.

The trial aims to evaluate whether Alzheimer’s disease can be slowed down by periodically extracting plasma from the patient’s body and replacing it with albumin, a protein. It has been conducted in people with mild or moderate Alzheimer’s disease in Spain and the United States.

The latest results strengthen Grifols’ research on plasma protein replacement therapies, the company said.
The trial showed that those patients treated with albumin and immunoglobulin had less of a reduction of the brain’s glucose metabolism after the 14-month-treatment, suggesting a reduction of the patients’ neuronal damage, it added.